NASHVILLE, Tenn., July 14 A newly available treatmentalready has benefited several individuals with aggressive malignancies.Offered through NeoPlas Innovation, this regimen has arrested or eradicatedtumors in more than 80% of initial patients. Director of Research Dr. StephenCantrell emphasized that human testing is in its early stages, but added,"These results have surprised us. This is far beyond what currently availablestandard treatments achieve."
Melanoma, a deadly form of malignant skin cancer, is among the diseasestargeted to date. The first person treated with the investigative protocol hadstage 4 melanoma and a life expectancy of eight weeks. He experienced acomplete response and remains disease-free eight years later. While not allresults have been this dramatic, each NeoPlas melanoma patient has had resultssignificantly better than those with standard therapy. Eradication of tumorsor long-term stability has occurred in most patients; others have seen asubstantial slowing of progression.
The new protocol incorporates a unique combination of FDA-approved drugsused by millions of people for other applications. When administered alone,these drugs show some benefit against cancer, but not enough to make adifference for most patients. The combination of the medicines, however,allows lower, more tolerable dosages and provides effectiveness not seen inprevious, single-drug studies.
The NeoPlas treatment disables certain abnormal cellular processes many ofthe aggressive malignancies share. Based on experience and relevant labresearch to date, staff members expect the best results for: melanoma,pancreatic cancer, colon cancer, renal (kidney) cancer, mesothelioma, and agroup of sarcomas, including osteosarcoma, chondrosarcoma and malignantfibrous histiocytoma. The regimen is not expected to have significant benefitagainst brain tumors.
The most notable side effect is fatigue. Most patients never experienceside effects commonly affiliated with chemotherapy or radiation (nausea,vomiting, hair loss, bone marrow suppression or immune system suppression). Anexperienced physician prescribes and monitors all treatment and maintainsclose communication with the patient's established oncologist. Having receivedprevious cancer treatments does not make a patient ineligible for theoutpatient NeoPlas regimen.
A Web site, www.neoplas.org, provides answers to common questions and aninteractive screening tool. Individuals can reach NeoPlas at 615-371-8100 orby e-mailing [email protected]
SOURCE NeoPlas Innovation